Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD

Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disorder, and yet with no pharmacological treatment approved worldwide. The repositioning of old drugs provides a safe approach for drug development. Vidofludimus, an inhibitor for dihydroorotate dehydrogenase (DHODH)...

詳細記述

保存先:
書誌詳細
出版年:Front Pharmacol
主要な著者: Zhu, Yanlin, Xu, Shuangshuang, Lu, Yi, Wei, Yijuan, Yao, Benqiang, Guo, Fusheng, Zheng, Xing, Wang, Yumeng, He, Ying, Jin, Lihua, Li, Yong
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2020
主題:
Pharmacology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7240069/
https://ncbi.nlm.nih.gov/pubmed/32477115
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00590
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料